CFM
ATRA icon

Catalyst Funds Management’s Atara Biotherapeutics ATRA Stock Holding History

Catalyst Funds Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100
Closed -$813 – 394
2024
Q3 		$813 Hold
100
– – ﹤0.01% 1265
2024
Q2 		$850 Buy
+100
New +$1.5K ﹤0.01% 1133

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Catalyst Funds Management's ATRA Position: Q4 2024 in Review

Catalyst Funds Management sold out of Atara Biotherapeutics (ATRA) in Q4 2024, closing a stake of 100 shares — an estimated $813 sold.

Catalyst Funds Management first reported a position in ATRA in Q2 2024 and held it in 2 quarters. The position peaked at $850 in Q2 2024. 43 funds tracked by Wall St. Rank hold ATRA as of Q4 2024.

  • Catalyst Funds Management reported no remaining Atara Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 100 Atara Biotherapeutics shares in Q4 2024, an estimated $813.
  • Catalyst Funds Management first reported a position in Atara Biotherapeutics in Q2 2024 and held it in 2 quarters.
  • Catalyst Funds Management's Atara Biotherapeutics position peaked at $850 in Q2 2024.
  • 43 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.